英妥木单抗(Intetumumab) - 药物靶点：CD51_专利_临床

概要

基本信息

药物类型

单克隆抗体

别名

Intetumumab (USAN/INN)、CNTO 095、CNTO-095

+ [1]

靶点

CD51

作用方式

拮抗剂

作用机制

CD51拮抗剂(整合素α-V拮抗剂)

治疗领域

肿瘤皮肤和肌肉骨骼疾病泌尿生殖系统疾病

在研适应症-

非在研适应症

晚期恶性实体瘤IV期恶性黑色素瘤黑色素瘤+ [2]

原研机构

Janssen Global Services LLC

在研机构-

非在研机构

Centocor, Inc.

BeOne Medicines Ltd.

Ajinomoto Althea, Inc.

权益机构

Janssen Pharmaceuticals, Inc.

BeOne Medicines Ltd.

最高研发阶段终止临床2期

首次获批日期-

最高研发阶段(中国)终止

特殊审评-

登录后查看时间轴

结构/序列

Sequence Code 1052166H

来源: *****

Sequence Code 1052172L

来源: *****

关联

3

项与英妥木单抗相关的临床试验

NCT00888043

/ Completed临床1期IIT

A Phase I/Biomarker Study of Bevacizumab in Combination With CNTO 95 in Patients With Refractory Solid Tumors

The purpose of this research study is to find out what side effects the combination of the two study drugs, bevacizumab (Avastin) and CNTO 95 have on the body and to determine the highest dose of CNTO 95 that can be given with bevacizumab that is safe and well tolerated.

开始日期2009-03-01

申办/合作机构

Duke University

[+2]

NCT00537381

/ Completed临床2期

A Randomized, Double-blind, Multicenter, Phase 2 Study of a Human Monoclonal Antibody to Human av Integrins (CNTO 95) in Combination With Docetaxel for the First-Line Treatment of Subjects With Metastatic Hormone Refractory Prostate Cancer

The purpose of this study is to assess the effects of intetumumab when given in combination with docetaxel and prednisone to participants with metastatic (spread of cancer cells from one part of the body to another) hormone-refractory (not responding to treatment) prostate cancer (abnormal tissue that grows and spreads in the body until it kills).

开始日期2007-05-01

申办/合作机构

Centocor, Inc.

NCT00246012

/ Completed临床1/2期

A Phase 1/2, Multi-Center, Blinded, Randomized, Controlled Study of the Safety and Efficacy of the Human Monoclonal Antibody to Human α ν Integrins (CNTO 95), Alone and in Combination With Dacarbazine, in Subjects With Stage IV Melanoma

The purpose of this study is to evaluate the safety and effectiveness of the intetumumab, alone and in combination with dacarbazine, in patients with stage 4 melanoma.

开始日期2005-05-01

申办/合作机构

Centocor, Inc.

100 项与英妥木单抗相关的临床结果

登录后查看更多信息

100 项与英妥木单抗相关的转化医学

登录后查看更多信息

100 项与英妥木单抗相关的专利（医药）

登录后查看更多信息

20

项与英妥木单抗相关的文献（医药）

2019-06-27·Anti-Cancer Agents in Medicinal Chemistry

Integrins as A New Target for Cancer Treatment

Review

作者: Mackiewicz, Jacek ; Łasiñska, Izabela

::

Integrins are responsible for intercellular adhesion and interaction with the cellular matrix. The function of integrins is related to the transduction of intracellular signals associated with adhesion, migration, cell proliferation, differentiation, and apoptosis. Molecules targeting integrins that lead to cancer cell death have been developed. The most advanced molecules studied in clinical trials are abituzumab, intetumumab and cilengitide. There are different groups of anti-integrin drugs: monoclonal antibodies (e.g., abituzumab) and other such as cilengitide, E7820 and MK-0429. These drugs have been evaluated in various cancer types. However, they have shown modest efficacy, and none of them have yet been approved for cancer treatment. Studies have shown that patient selection using biomarkers might improve the efficacy of anti-integrin cancer treatment. Many preclinical models have demonstrated promising results using integrin visualization for cancer detection and treatment efficacy monitoring; however, these strategies require further evaluation in humans.

2018-09-01·Journal of Cancer Research and Clinical Oncology

Effectiveness and tolerability of targeted drugs for the treatment of metastatic castration-resistant prostate cancer: a network meta-analysis of randomized controlled trials

Review

作者: Zhou, Zhansong ; Wang, Yongquan ; Shen, Wenhao ; Zhang, Heng ; He, Peng

PURPOSE:

Castration-resistant prostate cancer (CRPC) refers to prostate cancer that has progressed after initial androgen deprivation therapy (ADT). Over the years, treatment strategies for metastatic CRPC (mCRPC) have undergone considerable changes. We performed a network meta-analysis to assess the effectiveness and tolerability of targeted agents for mCRPC.

METHODS:

We search databases including MEDLINE, EMBASE, and the Cochrane Library through Sep 5, 2017. The major effectiveness outcomes were progression-free survival (PFS) and overall survival (OS). The tolerability outcome was severe adverse events (AEs) of grade ≥ 3.

RESULTS:

Twenty-six articles assessing a total of 20,314 patients were included in this study. A random-effect analysis showed that targeted agents could significant prolong PFS in mCRPC patients (I² = 94.3%; hazard ratio (HR): 0.74; 95% confidence interval (CI): 0.65-0.84; p < 0.001). In addition, the surface under the cumulative ranking curve (SUCRA) ranking from the network analysis showed that enzalutamide was the most effective in improving the PFS of mCRPC patients (100%), followed by abiraterone (90.1%) and tasquinimod (84.2%). Additionally, targeted agents could clearly prolong OS in mCRPC patients (I² = 71.6%; HR: 0.91; 95% CI: 0.85-0.97; p < 0.001). Furthermore, based on SUCRA ranking, enzalutamide was the most effective in improving the OS of mCRPC patients (97.2%), followed by abiraterone (91.1%) and zibotentan (65.8%). Intetumumab was associated with the lowest incidence of severe AEs (94.9%), followed by atrasentan (85.1%) and placebo (79.3%).

CONCLUSION:

In patients with mCRPC, enzalutamide, abiraterone and tasquinimod can prolong PFS, and enzalutamide and abiraterone can prolong OS. Additionally, enzalutamide and abiraterone can improve both PFS and OS with a low risk of causing severe AEs.

2015-02-01·Cancer chemotherapy and pharmacology4区 · 医学

A Phase I/biomarker study of bevacizumab in combination with CNTO 95 in patients with advanced solid tumors

4区 · 医学

Article

作者: Herbert I. Hurwitz ; Paula H. Lee ; Neal A. Ready ; Jingquan Jia ; Mark D. Starr ; Herbert Pang ; Johanna C. Bendell ; Leigh Howard ; Andrew B. Nixon ; Andrew Dellinger ; Hope E. Uronis

PURPOSE:

Inhibition of tumor angiogenesis is an effective mechanism to limit tumor growth; dual inhibition may result in additional benefit. Bevacizumab is a monoclonal antibody directed against vascular endothelial growth factor (VEGF), and intetumumab is a fully humanized monoclonal antibody that blocks αv integrins when complexed with β integrins. We evaluated the safety, tolerability, and efficacy of the combination of bevacizumab plus intetumumab in patients with refractory solid tumors. We also explored the effects of these agents on plasma-based biomarkers and wound angiogenesis.

METHODS:

Patients with refractory solid tumors, Karnofsky performance status ≥70%, and adequate organ function were eligible. Plasma samples and wound biopsies were obtained at baseline and on-treatment.

RESULTS:

Twelve patients were enrolled and received study drug. No tumor responses were noted. Observed toxicities included three cases of transient uveitis likely related to intetumumab and one case of reversible posterior leukoencephalopathy syndrome likely related to bevacizumab. Biomarker analysis revealed changes in soluble endoglin, soluble E-cadherin, and soluble E-selectin as well as PlGF and VEGF-D while on treatment. There was no observed impact of bevacizumab plus intetumumab on the phosphorylated or total levels of paxillin in wound tissue; however, an increase in the ratio of phospho/total paxillin levels was noted.

CONCLUSIONS:

Bevacizumab and intetumumab can be administered safely in combination. Bevacizumab plus intetumumab treatment resulted in changes in the plasma levels of several extracellular matrix interacting proteins and angiogenic factors.

100 项与英妥木单抗相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D09631	英妥木单抗	-	DB12701

研发状态

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
转移性去势抵抗性前列腺癌	临床2期	美国	Centocor, Inc.	2007-05-01
转移性去势抵抗性前列腺癌	临床2期	奥地利	Centocor, Inc.	2007-05-01
转移性去势抵抗性前列腺癌	临床2期	比利时	Centocor, Inc.	2007-05-01
转移性去势抵抗性前列腺癌	临床2期	德国	Centocor, Inc.	2007-05-01
转移性去势抵抗性前列腺癌	临床2期	印度	Centocor, Inc.	2007-05-01
转移性去势抵抗性前列腺癌	临床2期	荷兰	Centocor, Inc.	2007-05-01
转移性去势抵抗性前列腺癌	临床2期	波兰	Centocor, Inc.	2007-05-01
转移性去势抵抗性前列腺癌	临床2期	俄罗斯	Centocor, Inc.	2007-05-01
转移性去势抵抗性前列腺癌	临床2期	南非	Centocor, Inc.	2007-05-01
转移性去势抵抗性前列腺癌	临床2期	英国	Centocor, Inc.	2007-05-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT00246012 (CTgov)	临床1/2期	IV期恶性黑色素瘤	144	Intetumumab (Intetumumab 3 mg/kg [Phase 1 (Part 1)])	鬱構壓顧鹹構積淵餘襯 = 襯餘鬱顧襯遞膚醖壓顧艱鑰艱廠網淵顧餘壓簾 (製顧製餘窪鑰觸範壓選, 齋網襯鏇廠鬱鏇襯簾壓 ~ 鹽網顧淵顧顧鏇憲鬱衊) 更多	-	2013-08-19
				Intetumumab (Intetumumab 5 mg/kg [Phase 1 (Part 1)])	鬱構壓顧鹹構積淵餘襯 = 顧願鏇遞鑰簾鬱齋鏇選艱鑰艱廠網淵顧餘壓簾 (製顧製餘窪鑰觸範壓選, 獵繭觸選衊鏇艱襯艱餘 ~ 齋顧壓繭艱選觸憲繭繭) 更多
NCT00537381 (CTgov)	临床2期	转移性去势抵抗性前列腺癌	131	Placebo+prednisone+Docetaxel (Docetaxel + Prednisone + Placebo)	夢窪醖壓衊憲顧鹹鑰襯(鹽憲淵壓鹹製鹽範簾範) = 鏇鹹鹽製窪餘獵構蓋憲鏇蓋窪蓋遞齋範顧夢憲 (膚夢選膚網鬱製窪醖餘, 選餘壓鹹衊願襯壓鏇膚 ~ 憲艱積繭壓鏇窪鹹餘壓) 更多	-	2013-05-20
				prednisone+Docetaxel+Intetumumab (Docetaxel + Prednisone + Intetumumab)	夢窪醖壓衊憲顧鹹鑰襯(鹽憲淵壓鹹製鹽範簾範) = 構繭顧構襯夢鹹簾觸顧鏇蓋窪蓋遞齋範顧夢憲 (膚夢選膚網鬱製窪醖餘, 齋觸窪夢鏇鹹鏇艱鹽憲 ~ 膚壓簾廠襯範衊獵壓蓋) 更多
ASCO2009	临床2期	转移性黑色素瘤	-	CNTO 95 5mg/kg	觸願觸築衊築壓繭遞廠(獵壓網願淵膚積廠壓願) = 廠襯鏇鑰願衊願選網鑰憲願餘廠襯憲願積蓋憲 (淵網獵遞網遞範簾網顧 ) 更多	-	2009-05-20
				CNTO 95 10mg/kg	觸願觸築衊築壓繭遞廠(獵壓網願淵膚積廠壓願) = 積膚簾糧築鹹廠餘鹹醖憲願餘廠襯憲願積蓋憲 (淵網獵遞網遞範簾網顧 ) 更多
ASCO2004	临床1期	实体瘤	-	CNTO 95	膚選鹹鹹壓網遞鬱蓋廠(鑰鹽簾網窪蓋蓋積觸鏇) = An ileo-femoral DVT was seen in the first cohort 觸鏇襯餘構網選衊選壓 (鏇鹽糧淵構鹹顧鏇獵鹽 ) 更多	-	2004-07-15